可重新定位自膨胀经导管主动脉瓣的国际FORWARD研究临床结局
结果显示30天全因死亡率1.9%、致残性卒中1.8%,出院时中度及以上主动脉瓣反流1.9%,起搏器植入率17.5%,提示该瓣膜在老年高危患者中安全有效。
要点
- 1038例重度主动脉瓣狭窄患者TAVR后30天全因死亡率1.9%、致残性卒中1.8%。
- 98.9%患者瓣膜成功植入单枚至正确解剖位置,25.8%应用了重新定位功能。
- 出院时平均跨瓣压差8.5±5.6 mmHg,中度及以上主动脉瓣反流仅1.9%。
核心结论
- 使用新一代自膨胀经导管心脏瓣膜的TAVR对手术风险增高的老年重度主动脉瓣狭窄患者临床安全有效。
研究设计与样本
- 安全性终点由独立临床事件委员会依据VARC-2定义判定,所有超声心动图由独立核心实验室评估。
主要发现
- 患者平均年龄81.8±6.2岁,女性占64.9%,平均STS预测死亡风险5.5±4.5%,33.9%被评定为衰弱。
- 25.8%患者应用了瓣膜重新定位功能,98.9%患者将单枚瓣膜植入正确解剖位置。
- 出院时平均主动脉瓣压差8.5±5.6 mmHg,中度或重度主动脉瓣反流发生率1.9%。
- 30天全因死亡率1.9%,致残性卒中1.8%,起搏器植入率17.5%。
- 预期与观察的早期外科死亡率比值为0.35。
临床怎么用
- 对于手术风险增高的老年重度症状性主动脉瓣狭窄患者,可考虑使用该新一代可重新定位自膨胀瓣膜行TAVR。
局限性
- 本研究为单臂观察性研究,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical outcomes in large patient populations from real-world clinical practice with a next-generation self-expanding transcatheter aortic valve are lacking. OBJECTIVES: This study sought to document the clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with severe symptomatic aortic stenosis (AS) in routine clinical practice. METHODS: The FORWARD (CoreValve Evolut R FORWARD) study is a prospective, single-arm, multinational, multicenter, observational study. An independent clinical events committee adjudicated safety endpoints based on Valve Academic Research Consortium-2 definitions. An independent echocardiographic core laboratory evaluated all echocardiograms. From January 2016 to December 2016, TAVR with the next-generation self-expanding THV was attempted in 1,038 patients with symptomatic, severe AS at 53 centers on 4 continents. RESULTS: Mean age was 81.8 ± 6.2 years, 64.9% were women, the mean Society of Thoracic Surgeons Predicted Risk of Mortality was 5.5 ± 4.5%, and 33.9% of patients were deemed frail. The repositioning feature of the THV was applied in 25.8% of patients. A single valve was implanted in the proper anatomic location in 98.9% of patients. The mean aortic valve gradient was 8.5 ± 5.6 mm Hg, and moderate or severe aortic regurgitation was 1.9% at discharge. All-cause mortality was 1.9%, and disabling stroke occurred in 1.8% at 30 days. The expected-to-observed early surgical mortality ratio was 0.35. A pacemaker was implanted in 17.5% of patients. CONCLUSIONS: TAVR using the next-generation THV is clinically safe and effective for treating older patients with severe AS at increased operative risk. (CoreValve Evolut R FORWARD Study [FORWARD]; NCT02592369).
引用
- Grube E, Van Mieghem NM, Bleiziffer S, et al. Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study. J Am Coll Cardiol. 2017. PMID: 28797353. doi:10.1016/j.jacc.2017.06.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。